Evidence map›Paper›PMID 39863270›Full record

ArticleNeuropharmacology2025

Pharmacological characterization of the novel selective kappa opioid receptor agonists 10-Iodo-Akuammicine and 10-Bromo-akuammicine in mice.

Kathryn Bland, Chongguang Chen, Peng Huang, Conrad Ho, Theodora Howe, Katrina Ocampo, Pingwei Zhao, Simone Creed, Joseph Noel-Torres, Andrew P Riley and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Indole Alkaloids as Biased Opioid Receptor Modulators.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kathryn BlandCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Chongguang ChenCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Peng HuangCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Conrad HoCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Theodora HoweCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Katrina OcampoCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Pingwei ZhaoCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Simone CreedDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA.
Joseph Noel-TorresDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA.
Andrew P RileyDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA.
Lee-Yuan Liu-ChenCenter for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. Electronic address: lliuche@temple.edu.

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI SCOTT M. RAWLS · 2000 to 2026
$34.6M
Cellular Pharmacology of Kappa Opioid ReceptorR01DA017302 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI LIU-CHEN, LEE-YUAN · 2004 to 2013
$3.1M
Pharmacology of Kappa Opioid ReceptorR01DA041359 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI LIU-CHEN, LEE-YUAN · 2017 to 2021
$2.9M
Kappa Opioid Receptor in Paraventricular Nucleus of ThalamusR01DA056581 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI LEE-YUAN LIU-CHEN · 2023 to 2026
$2.3M
Synthesis and Evaluation of Alkaloids to Probe Membrane Receptors - Predoctoral SupplementR35GM147005 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Andrew Riley · 2022 to 2026
$2.3M
NIDA NIH HHS P30 DA013429NIDA NIH HHS R01 DA017302NIDA NIH HHS R01 DA041359NIDA NIH HHS R01 DA056581NIGMS NIH HHS R35 GM147005
6 · The paper itself

Abstract

Akuammicine (AKC), an indole alkaloid, is a kappa opioid receptor (KOR) full agonist with a moderate affinity. 10-Iodo-akuammicine (I-AKC) and 10-Bromo-akuammicine (Br-AKC) showed higher affinities for the KOR with K

Indexed as

Indole AlkaloidsReceptors, Opioid, kappa3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAnimalsDose-Response Relationship, DrugMaleMiceMotor Activity3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerIndole AlkaloidsReceptors, Opioid, kappaAkuammicineAnti-pruritic effectConditioned place aversionKappa opioid receptorKOR internalizationKOR phosphorylationLocomotor activityRotarod performance

Identifiers

PMID39863270
PMCPMC12173076

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.